3 completed, 1 terminated. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 3, Terminated 1 |
Follow Threshold Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma TH-302, Gemcitabine, Placebo (5 percent dextrose - D5W) - Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma | Phase 3 | Completed | ImmunoGenesis | 693 | 2012-12-01 | 2025-05-11 |
| A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma TH-302 in Combination with Doxorubicin, Doxorubicin - Soft Tissue Sarcoma | Phase 3 | Completed | Threshold Pharmaceuticals | 640 | 2011-09-01 | 2016-06-02 |
| Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia Lonidamine - Benign Prostatic Hyperplasia, Enlarged Prostate | Phase 3 | Terminated | Threshold Pharmaceuticals | 480 | 2005-06-01 | 2009-04-29 |
| Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer Glufosfamide - Pancreatic Cancer | Phase 3 | Completed | Threshold Pharmaceuticals | 300 | 2004-09-01 | 2009-04-30 |
Neoplasm Metastasis (2) · Pancreatic Neoplasms (2) · Neoplasms (1) · Prostatic Hyperplasia (1) · Sarcoma (1)
TH 302 (2) · Doxorubicin (1) · Gemcitabine (1) · beta-D-glucosylisophosphoramide mustard (1) · lonidamine (1)
Germany (3) · Hungary (3) · United States (3) · Italy (2) · Poland (2) · Russia (2) · Argentina (1) · Austria (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · Canada (1) · Czechia (1) · Denmark (1) · France (1)
Antonio Gualberto, MD, PhD (1) · Peter Alken, MD (1) · William Tap, MD (1)